Literature DB >> 19590042

Differential interferon responses enhance viral epitope generation by myocardial immunoproteasomes in murine enterovirus myocarditis.

Sandra Jäkel1, Ulrike Kuckelkorn, Gudrun Szalay, Michael Plötz, Kathrin Textoris-Taube, Elisa Opitz, Karin Klingel, Stefan Stevanovic, Reinhard Kandolf, Katja Kotsch, Karl Stangl, Peter M Kloetzel, Antje Voigt.   

Abstract

Murine models of coxsackievirus B3 (CVB3)-induced myocarditis mimic the divergent human disease course of cardiotropic viral infection, with host-specific outcomes ranging from complete recovery in resistant mice to chronic disease in susceptible hosts. To identify susceptibility factors that modulate the course of viral myocarditis, we show that type-I interferon (IFN) responses are considerably impaired in acute CVB3-induced myocarditis in susceptible mice, which have been linked to immunoproteasome (IP) formation. Here we report that in concurrence with distinctive type-I IFN kinetics, myocardial IP formation peaked early after infection in resistant mice and was postponed with maximum IP expression concomitant to massive inflammation and predominant type-II IFN responses in susceptible mice. IP activity is linked to a strong enhancement of antigenic viral peptide presentation. To investigate the impact of myocardial IPs in CVB3-induced myocarditis, we identified two novel CVB3 T cell epitopes, virus capsid protein 2 [285-293] and polymerase 3D [2170-2177]. Analysis of myocardial IPs in CVB3-induced myocarditis revealed that myocardial IP expression resulted in efficient epitope generation. As opposed to the susceptible host, myocardial IP expression at early stages of disease corresponded to enhanced CVB3 epitope generation in the hearts of resistant mice. We propose that this process may precondition the infected heart for adaptive immune responses. In conclusion, type-I IFN-induced myocardial IP activity at early stages coincides with less severe disease manifestation in CVB3-induced myocarditis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590042      PMCID: PMC2716952          DOI: 10.2353/ajpath.2009.090033

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

Review 1.  Antigen processing by the proteasome.

Authors:  P M Kloetzel
Journal:  Nat Rev Mol Cell Biol       Date:  2001-03       Impact factor: 94.444

Review 2.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

3.  Advances in the understanding of myocarditis.

Authors:  P P Liu; J W Mason
Journal:  Circulation       Date:  2001-08-28       Impact factor: 29.690

4.  Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver.

Authors:  S Khan; M van den Broek; K Schwarz; R de Giuli; P A Diener; M Groettrup
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

5.  Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication.

Authors:  R Wessely; K Klingel; K U Knowlton; R Kandolf
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

6.  MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.

Authors:  A J Sijts; S Standera; R E Toes; T Ruppert; N J Beekman; P A van Veelen; F A Ossendorp; C J Melief; P M Kloetzel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

7.  Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope.

Authors:  K Schwarz; M van Den Broek; S Kostka; R Kraft; A Soza; G Schmidtke; P M Kloetzel; M Groettrup
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

8.  Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.

Authors:  A Henke; R Zell; G Ehrlich; A Stelzner
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

Authors:  Robin J Prestwich; Fiona Errington; Elizabeth J Ilett; Ruth S M Morgan; Karen J Scott; Timothy Kottke; Jill Thompson; Ewan E Morrison; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

10.  Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28.

Authors:  A Sijts; M Camps; R Offringa; C Melief; P M Kloetzel; F Ossendorp
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  14 in total

Review 1.  Type B coxsackieviruses and their interactions with the innate and adaptive immune systems.

Authors:  Christopher C Kemball; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

2.  Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo.

Authors:  Christopher C Kemball; Claudia T Flynn; Martin P Hosking; Jason Botten; J Lindsay Whitton
Journal:  Virology       Date:  2012-05-01       Impact factor: 3.616

3.  Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection.

Authors:  Mary K McCarthy; Danielle H Malitz; Caitlyn T Molloy; Megan C Procario; Kaitlyn E Greiner; Luna Zhang; Ping Wang; Sharlene M Day; Saul R Powell; Jason B Weinberg
Journal:  Virology       Date:  2016-08-22       Impact factor: 3.616

Review 4.  The Macrophage in Cardiac Homeostasis and Disease: JACC Macrophage in CVD Series (Part 4).

Authors:  Kory J Lavine; Alexander R Pinto; Slava Epelman; Benjamin J Kopecky; Xavier Clemente-Casares; James Godwin; Nadia Rosenthal; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2018-10-30       Impact factor: 24.094

Review 5.  The role of the proteasome in the generation of MHC class I ligands and immune responses.

Authors:  E J A M Sijts; P M Kloetzel
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

6.  Impairment of immunoproteasome function by β5i/LMP7 subunit deficiency results in severe enterovirus myocarditis.

Authors:  Elisa Opitz; Annett Koch; Karin Klingel; Frank Schmidt; Stefan Prokop; Anna Rahnefeld; Martina Sauter; Frank L Heppner; Uwe Völker; Reinhard Kandolf; Ulrike Kuckelkorn; Karl Stangl; Elke Krüger; Peter M Kloetzel; Antje Voigt
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

7.  Cardiac Function Remains Impaired Despite Reversible Cardiac Remodeling after Acute Experimental Viral Myocarditis.

Authors:  Peter Moritz Becher; Frauke Gotzhein; Karin Klingel; Felicitas Escher; Stefan Blankenberg; Dirk Westermann; Diana Lindner
Journal:  J Immunol Res       Date:  2017-03-02       Impact factor: 4.818

8.  PA28 modulates antigen processing and viral replication during coxsackievirus B3 infection.

Authors:  Dorota Respondek; Martin Voss; Ina Kühlewindt; Karin Klingel; Elke Krüger; Antje Beling
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

9.  The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis.

Authors:  Nadine Althof; Carl Christoph Goetzke; Meike Kespohl; Karolin Voss; Arnd Heuser; Sandra Pinkert; Ziya Kaya; Karin Klingel; Antje Beling
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

10.  ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.

Authors:  Hannah Louise Neumaier; Shelly Harel; Karin Klingel; Ziya Kaya; Arnd Heuser; Meike Kespohl; Antje Beling
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.